Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Trials

MRD trials

The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov set of studies that are recruiting or not yet recruiting. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.

Recruiting and not-yet-recruiting studies that use ctDNA, cfDNA, or MRD in eligibility, a treatment decision, or a primary or secondary endpoint, plus observational studies focused on that testing. 1123 studies from 2267 registry records. Hematologic trials that list MRD only as a secondary endpoint are listed separately. Last synced Nov 18, 2026, 2:04 PM EST.

  • Heme · AMLRecruitingPhase 3NCT07007312

    Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

    Kura Oncology, Inc. · 141 locations · Updated 2026-11-12

  • Heme · AMLRecruitingPhase 3NCT07539818

    Azacitidine + Venetoclax VS Azacitidineas Maintenance Therapy in AML

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-10-26

  • Heme · AMLRecruitingPhase 3NCT07211958

    Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

    Syndax Pharmaceuticals · 173 locations · Updated 2026-10-21

  • Heme · AMLRecruitingPhase 2 / Phase 3NCT03013998

    Study of Biomarker-Based Treatment of Acute Myeloid Leukemia

    Beat AML, LLC · 31 locations · Updated 2026-09-03

  • Heme · AMLNot yet recruitingPhase 3NCT07761702

    Umbilical Cord Blood Consolidation for Older Adults With Intermediate- and High-Risk AML

    Shanghai Jiao Tong University School of Medicine · Locations not reported · Updated 2026-08-12

  • Heme · AMLNot yet recruitingPhase 3NCT07686965

    Lisaftoclax Plus Azacitidine Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia Patients at High Risk of Relapse

    Institute of Hematology & Blood Diseases Hospital, China · Locations not reported · Updated 2026-07-07

  • Heme · AMLRecruitingPhase 3NCT07463651

    MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib

    The First Affiliated Hospital of Soochow University · 2 locations · Updated 2026-03-20

  • Heme · AMLNot yet recruitingPhase 2 / Phase 3NCT07264010

    Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

    Nanfang Hospital, Southern Medical University · Locations not reported · Updated 2025-12-04

  • Heme · AMLRecruitingPhase 3NCT06802718

    Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia

    Peking University People's Hospital · 1 locations · Updated 2025-01-31

  • Heme · AMLRecruitingPhase 3NCT04168502

    Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML

    Gruppo Italiano Malattie EMatologiche dell'Adulto · 48 locations · Updated 2024-11-08

  • Heme · Myeloma, AMLRecruitingPhase 2NCT07437950

    Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

    National Cancer Institute (NCI) · 69 locations · Updated 2026-11-18

  • Heme · Myeloma, AMLRecruitingPhase 2NCT06672146

    Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

    National Cancer Institute (NCI) · 138 locations · Updated 2026-11-16

  • Heme · Myeloma, AMLRecruitingPhase 2NCT06317649

    Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

    National Cancer Institute (NCI) · 229 locations · Updated 2026-11-12

  • Heme · AMLRecruitingPhase 2NCT07925554

    Interferon-α Maintenance in Favorable-Risk AML

    Peking University People's Hospital · 1 locations · Updated 2026-11-09

  • Heme · Myeloma, AMLRecruitingPhase 2NCT05554406

    Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

    National Cancer Institute (NCI) · 227 locations · Updated 2026-11-09

  • Heme · Myeloma, AMLRecruitingPhase 2NCT06917911

    Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MYELOMATCH Treatment Trial)

    National Cancer Institute (NCI) · 81 locations · Updated 2026-11-04

  • Heme · Myeloma, AMLRecruitingPhase 2NCT05554393

    Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

    National Cancer Institute (NCI) · 187 locations · Updated 2026-10-28

  • Heme · AMLRecruitingPhase 2NCT07228273

    Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia

    OHSU Knight Cancer Institute · 1 locations · Updated 2026-10-20

  • Heme · Myeloma, AMLNot yet recruitingPhase 2NCT06954987

    Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

    National Cancer Institute (NCI) · Locations not reported · Updated 2026-10-20

  • Heme · AMLNot yet recruitingPhase 2NCT07572929

    A Pragmatic Clinical Trial to Prevent Relapse for Myeloid Malignancies With Measurable Disease Prior to Allogeneic Transplant

    Medical College of Wisconsin · 1 locations · Updated 2026-10-13

  • Heme · AMLRecruitingPhase 2NCT07060001

    Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

    The Methodist Hospital Research Institute · 1 locations · Updated 2026-10-08

  • Heme · Myeloma, AMLNot yet recruitingPhase 2NCT07862517

    Testing the Investigational Medication Combination of Azacitidine, Venetoclax, and Quizartinib Compared to the Usual Treatment of Cytarabine, Daunorubicin, and Quizartinib for Patients With FLT3-ITD Mutant Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

    National Cancer Institute (NCI) · Locations not reported · Updated 2026-10-07

  • Heme · Myeloma, AMLNot yet recruitingPhase 2NCT05554419

    Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia Following Initial Treatment, The ERASE Study (A MyeloMATCH Treatment Trial)

    National Cancer Institute (NCI) · Locations not reported · Updated 2026-10-01

  • Heme · AMLRecruitingPhase 2NCT05955261

    A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia

    St. Jude Children's Research Hospital · 10 locations · Updated 2026-09-17

  • Heme · Myeloma, AMLNot yet recruitingPhase 2NCT07153497

    Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

    National Cancer Institute (NCI) · Locations not reported · Updated 2026-09-09

  • Heme · AMLRecruitingPhase 2NCT05904106

    Venetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AML

    Technische Universität Dresden · 18 locations · Updated 2026-08-27

  • Heme · AMLNot yet recruitingPhase 1 / Phase 2NCT07766850

    Addition of Hydroxyurea to Fludarabine, Cytarabine, Idarubicin and Venetoclax Salvage Therapy for Adults With Relapsed or Refractory Acute Myeloid Leukemia

    Christer C Nilsson · 1 locations · Updated 2026-08-17

  • Heme · AMLRecruitingPhase 1 / Phase 2NCT07761533

    PBSS1113 in Combination With Azacitidine to Treat Patients With AML/MDS

    Chaser Therapeutics, Inc. · 1 locations · Updated 2026-08-14

  • Heme · AMLRecruitingPhase 2NCT03737955

    Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia

    University of Washington · 1 locations · Updated 2026-08-13

  • Heme · AMLRecruitingPhase 2NCT06529731

    Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation

    Sawa Ito, MD · 3 locations · Updated 2026-08-11

  • Heme · AMLNot yet recruitingPhase 2NCT07748455

    HMA-Venetoclax Induction in Newly Diagnosed AML

    Pakistan Blood and Marrow Transplant (PBMT) Group · 1 locations · Updated 2026-08-05

  • Heme · AMLRecruitingPhase 2NCT07392970

    Motixafortide for MRD Sensitization in AML

    Washington University School of Medicine · 1 locations · Updated 2026-07-24

  • Heme · AMLNot yet recruitingPhase 1 / Phase 2NCT07726576

    Venetoclax in Association With 3+7 and Midostaurin in FLT3-mutated Acute Myeloid Leukemia

    University Hospital, Bordeaux · 3 locations · Updated 2026-07-24

  • Heme · AMLRecruitingPhase 2NCT04050280

    CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

    University of Maryland, Baltimore · 1 locations · Updated 2026-07-01

  • Heme · Myeloma, ALL, CLL, AML, LymphomaRecruitingPhase 2NCT03314974

    Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

    Masonic Cancer Center, University of Minnesota · 1 locations · Updated 2026-06-25

  • Heme · AMLRecruitingPhase 1 / Phase 2NCT06611839

    Venetoclax in Combination With Ivosidenib and Azacitidine for Newly Diagnosed IDH1-Mutated AML

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-05-13

  • Heme · AMLRecruitingPhase 2NCT07563179

    Bugitinib Combined With Venetoclax and Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia

    Shenzhen University General Hospital · 1 locations · Updated 2026-05-01

  • Heme · AMLRecruitingPhase 2NCT06660368

    BCL2i CLAG-M in R/R Acute Myeloid Leukemia

    H. Lee Moffitt Cancer Center and Research Institute · 2 locations · Updated 2026-04-01

  • Heme · AMLRecruitingPhase 2NCT05260528

    CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics

    Centre Hospitalier Universitaire de Nice · 35 locations · Updated 2026-03-27

  • Heme · AMLRecruitingPhase 2NCT06557421

    De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients

    Institut Paoli-Calmettes · 1 locations · Updated 2026-03-13

Showing 1–40 of 100. Older studies

More hematologic trials (126) that list MRD only as a secondary endpoint
  • Heme · AMLRecruitingPhase 3NCT07925190

    A Study Comparing Mesutoclax + Azacitidine Versus Venetoclax + Azacitidine in Untreated Acute Myeloid Leukemia (AML) Patients

    Beijing InnoCare Pharma Tech Co., Ltd. · 1 locations · Updated 2026-11-13

  • Heme · AMLRecruitingPhase 3NCT04628026

    Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2

    University of Ulm · 91 locations · Updated 2026-11-12

  • Heme · AMLRecruitingPhase 3NCT06852222

    A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

    Janssen Research & Development, LLC · 270 locations · Updated 2026-11-03

  • Heme · AMLRecruitingPhase 3NCT07132684

    Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-10-26

  • Heme · AMLRecruitingPhase 3NCT04293562

    A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

    Children's Oncology Group · 206 locations · Updated 2026-09-17

  • Heme · AMLNot yet recruitingPhase 2 / Phase 3NCT07623187

    A Study to Assess How Well the Study Medicine IPN60340 Works in Combination With Azacitidine and Venetoclax, Compared to Placebo in Combination With Azacitidine and Venetoclax, in Participants With Newly Diagnosed Acute Myeloid Leukemia Who Cannot Receive Intensive Chemotherapy

    Ipsen · Locations not reported · Updated 2026-09-10

  • Heme · AMLRecruitingPhase 3NCT07514936

    Venetoclax-Azacitidine in Combination With Chidamide and CAG in Fit Older Patients With Acute Myeloid Leukaemia

    Chinese PLA General Hospital · 1 locations · Updated 2026-08-20

  • Heme · AMLRecruitingPhase 3NCT06744504

    Standard-dose vs Intermediate-dose Cytarabine Induction in the Treatment of Acute Myeloid Leukemia With RUNX1-RUNX1T1

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-08-07

  • Heme · AMLNot yet recruitingPhase 3NCT07735117

    Mitoxantrone Hydrochloride Liposome, Cytarabine, G-CSF Plus Venetoclax vs. Azacitidine Plus Venetoclax for MDS-IB2 and Secondary/Elderly AML

    Ruijin Hospital · Locations not reported · Updated 2026-07-29

  • Heme · AMLRecruitingPhase 3NCT07712848

    DEC3-VEN vs. Venetoclax-Based vs. DA Regimens in Newly Diagnosed AML

    The Second Affiliated Hospital of Kunming Medical University · 1 locations · Updated 2026-07-20

  • Heme · AMLNot yet recruitingPhase 3NCT07469046

    VAH vs VA in Newly Diagnosed Elderly AML

    Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · 1 locations · Updated 2026-04-13

  • Heme · AMLNot yet recruitingPhase 3NCT07407140

    VAG Versus Standard Chemotherapy With FLT3 Inhibitor in Adult Patients With FLT3-Mutated AML

    Institute of Hematology & Blood Diseases Hospital, China · Locations not reported · Updated 2026-03-25

  • Heme · AMLNot yet recruitingPhase 3NCT07486479

    Venetoclax, Azacitidine, and Mitoxantrone Hydrochloride Liposome Versus Idarubicin and Cytarabine in Newly Diagnosed AML

    The First Affiliated Hospital of Soochow University · 21 locations · Updated 2026-03-20

  • Heme · AMLNot yet recruitingPhase 3NCT07407660

    Shortened Venetoclax Duration Based on Day 14 BM Blasts Versus Standard Therapy in Elderly or Frail Patients With AML Patients Treated With Azacitidine Plus Venetoclax

    Peking University People's Hospital · Locations not reported · Updated 2026-02-12

  • Heme · AMLRecruitingPhase 3NCT07075016

    Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy

    Stichting Hemato-Oncologie voor Volwassenen Nederland · 119 locations · Updated 2025-08-19

  • Heme · AMLRecruitingPhase 3NCT06990321

    Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia

    Yehui Tan · 1 locations · Updated 2025-08-08

  • Heme · AMLRecruitingPhase 3NCT05994690

    CHIP-AML22/Master: An Open Label Complex Clinical Trial in Newly Diagnosed Pediatric de Novo AML Patients

    Princess Maxima Center for Pediatric Oncology · 1 locations · Updated 2025-08-05

  • Heme · AMLRecruitingPhase 3NCT06810791

    HVA vs IA/DA or VA in the Treatment of ND HR-AML

    Nanfang Hospital, Southern Medical University · 1 locations · Updated 2025-02-06

  • Heme · AMLNot yet recruitingPhase 3NCT05876832

    A Study of XY0206 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory AML With FLT3-ITD-Mutation (ALIVE)

    Shijiazhuang Yiling Pharmaceutical Co. Ltd · Locations not reported · Updated 2023-05-26

  • Heme · AMLRecruitingPhase 2 / Phase 3NCT05404906

    AZA + Venetoclax as Maintenance Therapy in Younger Adults With AML in First Remission

    The First Affiliated Hospital of Soochow University · 2 locations · Updated 2022-08-19

  • Heme · AMLRecruitingPhase 2NCT07507760

    Oral Decitabine Plus Ivosidenib as First Line for Older/Unfit Adult AML Patients

    PETHEMA Foundation · 21 locations · Updated 2026-11-17

  • Heme · AMLNot yet recruitingPhase 1 / Phase 2NCT07939971

    A Study of TBS-2025 Monotherapy in Participants With r/r NPM1mut AML

    TuHURA Biosciences, Inc. · Locations not reported · Updated 2026-11-16

  • Heme · AMLNot yet recruitingPhase 1 / Phase 2NCT07722312

    S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation

    Servier · Locations not reported · Updated 2026-11-16

  • Heme · ALL, AMLNot yet recruitingPhase 2NCT07937124

    An All-Oral Combination of Ivosidenib, Sonrotoclax, and Chidamide for Newly Diagnosed Acute Myeloid Leukemia With an IDH1 Mutation (ISC)

    First Affiliated Hospital of Zhejiang University · Locations not reported · Updated 2026-11-13

  • Heme · AMLRecruitingPhase 1 / Phase 2NCT04774393

    Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

    M.D. Anderson Cancer Center · 1 locations · Updated 2026-11-12

  • Heme · ALL, AMLNot yet recruitingPhase 1 / Phase 2NCT07926607

    Palbociclib, All-Trans Retinoic Acid, and Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia

    Second Affiliated Hospital of Nanchang University · 1 locations · Updated 2026-11-09

  • Heme · AMLRecruitingPhase 2NCT06930352

    Ziftomenib for the Treatment of Patients With NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia Not Eligible for Standard Therapy

    Uma Borate · 1 locations · Updated 2026-11-09

  • Heme · AMLRecruitingPhase 1 / Phase 2NCT04797767

    Venetoclax and CLAG-M for the Treatment of Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms

    University of Washington · 1 locations · Updated 2026-11-06

  • Heme · AMLNot yet recruitingPhase 2NCT07605949

    Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AML

    UNC Lineberger Comprehensive Cancer Center · 1 locations · Updated 2026-11-05

  • Heme · ALL, AMLRecruitingPhase 2NCT03970096

    Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

    Fred Hutchinson Cancer Center · 3 locations · Updated 2026-10-20

  • Heme · AMLRecruitingPhase 1 / Phase 2NCT04140487

    Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

    M.D. Anderson Cancer Center · 1 locations · Updated 2026-10-06

  • Heme · AMLRecruitingPhase 2NCT06707493

    Ivosidenib as Post-HSCT Maintenance for AML

    Massachusetts General Hospital · 7 locations · Updated 2026-10-05

  • Heme · AMLNot yet recruitingPhase 2NCT07755202

    Gilteritinib-Azacitidine-Venetoclax Combination Therapy in Patients With Relapsed/Refractory Leukemia

    Florian Kuchenbauer · 1 locations · Updated 2026-10-02

  • Heme · AMLRecruitingPhase 2NCT06014489

    A Trial to Assess Cobicistat Boosted Venetoclax in Combination With Azacitidine in Adult Patients With Newly Diagnosed AML

    Stichting Hemato-Oncologie voor Volwassenen Nederland · 19 locations · Updated 2026-09-23

  • Heme · AMLRecruitingPhase 2NCT07710534

    Metronomic Decitabine-Cedazuridine and Venetoclax in R/R AML, HR-MDS, HR/AP MPN

    Virginia Commonwealth University · 1 locations · Updated 2026-09-21

  • Heme · AMLRecruitingPhase 1 / Phase 2NCT05010122

    ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

    M.D. Anderson Cancer Center · 1 locations · Updated 2026-09-04

  • Heme · AMLNot yet recruitingPhase 2NCT07754799

    A Randomized Trial of Venetoclax-Based Induction Intensity in Newly Diagnosed Acute Myeloid Leukemia

    Institute of Hematology & Blood Diseases Hospital, China · Locations not reported · Updated 2026-08-26

  • Heme · AMLNot yet recruitingPhase 1 / Phase 2NCT07757672

    Salvage Chemotherapy With Sonrotoclax, Cladribine, and Standard-dose Cytarabine, Sequentially Followed by HSCT for R/R AML.

    Institute of Hematology & Blood Diseases Hospital, China · Locations not reported · Updated 2026-08-11

  • Heme · AML, LymphomaNot yet recruitingPhase 1 / Phase 2NCT07749976

    GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors

    Vitruviae · Locations not reported · Updated 2026-08-06

  • Heme · AMLRecruitingPhase 2NCT07672262

    VA Consolidation in Intermediate-Risk AML

    The First Affiliated Hospital of Soochow University · 1 locations · Updated 2026-08-06

  • Heme · AMLRecruitingPhase 2NCT07425782

    Venetoclax Combined With Azacitidine for Consolidation Therapy in AML

    The First Affiliated Hospital of Soochow University · 1 locations · Updated 2026-08-06

  • Heme · AMLRecruitingPhase 2NCT07548710

    Study of SA+X in the Treatment of Newly Diagnosed AML

    Ruijin Hospital · 1 locations · Updated 2026-07-30

  • Heme · AMLRecruitingPhase 2NCT07046078

    Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

    Fred Hutchinson Cancer Center · 1 locations · Updated 2026-07-20

  • Heme · AMLRecruitingPhase 2NCT05442216

    Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

    Joshua Zeidner · 7 locations · Updated 2026-07-10

  • Heme · AMLNot yet recruitingPhase 2NCT07664839

    Study on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 Mutations

    Shen yang · 1 locations · Updated 2026-06-24

  • Heme · AMLRecruitingPhase 1 / Phase 2NCT07663864

    Luspatercept for CIA in AML

    Guangdong Second Provincial General Hospital · 1 locations · Updated 2026-06-23

  • Heme · AMLNot yet recruitingPhase 2NCT07643636

    Chidamide, Venetoclax, Azacitidine, and Homoharringtonine for High-risk Fit AML

    Dongguan People's Hospital · Locations not reported · Updated 2026-06-18

  • Heme · AMLNot yet recruitingPhase 2NCT07642453

    VA-CAG Two-Week vs. Three-Week Regimen for Induction Remission in Newly Diagnosed Acute Myeloid Leukemia.

    Hematology department of the 920th hospital · Locations not reported · Updated 2026-06-11

  • Heme · AMLRecruitingPhase 2NCT07623616

    A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

    Kyowa Kirin Co., Ltd. · 20 locations · Updated 2026-06-03

  • Heme · AMLRecruitingPhase 2NCT06635681

    Efficacy of Venetoclax Combined With Intensive Chemotherapy in Different Subgroups of AML

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-05-13

  • Heme · AMLRecruitingPhase 2NCT06928376

    A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients

    Chinese PLA General Hospital · 1 locations · Updated 2026-05-08

  • Heme · AMLRecruitingPhase 2NCT06782542

    Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy

    Justin Watts, MD · 1 locations · Updated 2026-04-16

  • Heme · AMLRecruitingPhase 1 / Phase 2NCT06561152

    Tagraxofusp and Low-Intensity Chemotherapy for CD123-Positive Relapsed or Refractory AML

    Stanford University · 1 locations · Updated 2026-04-14

  • Heme · Myeloma, ALL, CLL, AML, LymphomaRecruitingPhase 1 / Phase 2NCT07523555

    Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

    Beijing Biotech · 1 locations · Updated 2026-04-13

  • Heme · AMLRecruitingPhase 2NCT07514832

    VA-CIG Regimen for Previously Untreated Acute Myeloid Leukemia: A Multicenter Prospective Single-Arm Trial

    Beijing 302 Hospital · 1 locations · Updated 2026-04-07

  • Heme · AMLRecruitingPhase 2NCT06084819

    Clinical Study of Venetoclax Combined With CACAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

    Chinese PLA General Hospital · 1 locations · Updated 2026-04-02

  • Heme · AMLNot yet recruitingPhase 2NCT07507825

    Exploratory Study of Venetoclax, Homoharringtonine, Azacitidine Plus G-CSF for Newly Diagnosed AML (VHAG)

    First People's Hospital of Hangzhou · 1 locations · Updated 2026-04-02

  • Heme · ALL, AMLRecruitingPhase 1 / Phase 2NCT07471789

    Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).

    Gyala Therapeutics · 2 locations · Updated 2026-03-13

  • Heme · AMLNot yet recruitingPhase 2NCT07463768

    Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in Complete Remission After Intensive Chemotherapy.

    French Innovative Leukemia Organisation · 20 locations · Updated 2026-03-11

  • Heme · AMLRecruitingPhase 1 / Phase 2NCT07451912

    Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML

    The First Affiliated Hospital of Soochow University · 1 locations · Updated 2026-03-05

  • Heme · AMLRecruitingPhase 2NCT05917405

    Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT

    Nantes University Hospital · 23 locations · Updated 2026-01-30

  • Heme · AMLRecruitingPhase 2NCT07304232

    Post-transplantation Maintenance Therapy With Cidabenamide in Patients With Intermediate/High-risk AML

    Institute of Hematology & Blood Diseases Hospital, China · 5 locations · Updated 2025-12-26

  • Heme · ALL, AML, LymphomaRecruitingPhase 1 / Phase 2NCT07153068

    SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2025-12-15

  • Heme · ALL, AMLRecruitingPhase 2NCT07256210

    Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation

    Federal Research Institute of Pediatric Hematology, Oncology and Immunology · 1 locations · Updated 2025-12-01

  • Heme · AMLRecruitingPhase 2NCT06451861

    Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML

    Guangdong Provincial People's Hospital · 13 locations · Updated 2025-11-17

  • Heme · AMLNot yet recruitingPhase 1 / Phase 2NCT06281847

    An Adaptive Open-label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of CCTx-001, and to Assess Safety, Tolerability, and Clinical Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia

    Advesya SAS · 6 locations · Updated 2025-09-18

  • Heme · AMLRecruitingPhase 2NCT06156579

    Combination Salvage Therapy With Venetoclax and Decitabine in Relapsed/Refractory AML

    University Hospital Tuebingen · 1 locations · Updated 2025-04-08

  • Heme · AMLRecruitingPhase 2NCT02781883

    Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

    Bio-Path Holdings, Inc. · 9 locations · Updated 2025-03-07

  • Heme · AMLRecruitingPhase 2NCT06783790

    Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2025-01-20

  • Heme · AMLRecruitingPhase 1 / Phase 2NCT05601726

    First-in-human Study Aiming to Characterize the Safety, Tolerability, Pharmacokinetic and Preliminary Signs of Activity of ABD-3001 in Refractory or Relapsed AML and High Risk MDS Adult Patients

    Advanced BioDesign · 3 locations · Updated 2025-01-20

  • Heme · AMLNot yet recruitingPhase 2NCT06783478

    NK Cell Infusion for Remission Consolidation in AML: A Phase II Trial

    Hospital de Clinicas de Porto Alegre · 1 locations · Updated 2025-01-20

  • Heme · AMLRecruitingPhase 2NCT06621199

    Mitoxantrone Hydrochloride Liposome in Combination With Cytarabine and Venetoclax Regimen in Newly Diagnosed Elderly AML

    First Affiliated Hospital of Zhejiang University · 1 locations · Updated 2024-10-01

  • Heme · AMLRecruitingPhase 2NCT06537843

    Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia

    Hospital Municipal São José · 5 locations · Updated 2024-08-05

  • Heme · AMLRecruitingPhase 2NCT04905810

    Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

    Brian Jonas · 4 locations · Updated 2024-05-29

  • Heme · AMLNot yet recruitingPhase 1 / Phase 2NCT06387420

    A Study of AK117 in Combination With Azactidine Plus Venetoclax in Patients With Acute Myeloid Leukemia

    Akeso · 1 locations · Updated 2024-04-29

  • Heme · AMLNot yet recruitingPhase 2NCT06050941

    Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS

    First Affiliated Hospital of Zhejiang University · Locations not reported · Updated 2024-03-05

  • Heme · AMLRecruitingPhase 1 / Phase 2NCT06125652

    Administration of Anti Tim-3/CD123 CAR-T Cell Therapy in Relapsed and Refractory Acute Myeloid Leukemia (rr/AML)

    Xuzhou Medical University · 1 locations · Updated 2023-11-09

  • Heme · AMLRecruitingPhase 2NCT05736965

    A Study of Selinexor in Combination With Azacitidine and Venetoclax (SAV Regimen) in Treatment Naïve Participants With Acute Myeloid Leukemia

    Shanghai Tong Ren Hospital · 19 locations · Updated 2023-03-15

  • Heme · AMLRecruitingPhase 2NCT05736978

    Adaptive Treatment for Acute Myeloid Leukemia Based on D14 MRD Results

    Shanghai Tong Ren Hospital · 4 locations · Updated 2023-03-15

  • Heme · AMLRecruitingPhase 4NCT06370000

    Oral Azacitidine in Transplant-Eligible Patients With Acute Myeloid Leukemia (AML) Suffering From Health-Inequality

    Virginia Commonwealth University · 1 locations · Updated 2026-11-05

  • Heme · CLL, AMLNot yet recruitingPhase 1NCT07897136

    CLL-1/CD70 Dual-Target CAR-T Cell Therapy for Acute Myeloid Leukemia

    Liping Dou · 1 locations · Updated 2026-10-27

  • Heme · AMLRecruitingPhase 1NCT07347418

    CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML

    University of Colorado, Denver · 1 locations · Updated 2026-10-20

  • Heme · ALL, AMLRecruitingPhase 1NCT06575296

    Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant

    City of Hope Medical Center · 1 locations · Updated 2026-10-19

  • Heme · CLL, AMLNot yet recruitingPhase 1NCT07841002

    CLL-1-Targeted In Vivo CAR-T Cell Immunotherapy for Relapsed/Refractory Acute Myeloid Leukemia

    Liping Dou · 1 locations · Updated 2026-10-02

  • Heme · AMLRecruitingPhase 1NCT06763341

    A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    City of Hope Medical Center · 1 locations · Updated 2026-09-29

  • Heme · AMLNot yet recruitingPhase 1NCT07828535

    Liposomal Mitoxantrone Plus Azacitidine and Venetoclax in Newly Diagnosed Elderly or Unfit AML

    Institute of Hematology & Blood Diseases Hospital, China · Locations not reported · Updated 2026-09-18

  • Heme · AMLRecruitingNot reportedObservationalNCT05587049

    A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Receiving Oral Venetoclax Tablets in Combination With Subcutaneously (SC) or Intravenously (IV) Injected Azacitidine in Colombia

    AbbVie · 8 locations · Updated 2026-08-26

  • Heme · AMLRecruitingPhase 1NCT07439211

    Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia

    Jacqueline Garcia, MD · 2 locations · Updated 2026-08-26

  • Heme · AMLRecruitingEarly Phase 1NCT07059975

    UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

    Baylor College of Medicine · 1 locations · Updated 2026-08-24

  • Heme · AMLRecruitingPhase 1NCT06001788

    Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    Kura Oncology, Inc. · 45 locations · Updated 2026-08-20

  • Heme · AMLRecruitingNot applicableNCT06265545

    Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-08-07

  • Heme · AMLRecruitingNot applicableNCT07490288

    Venetoclax, Azacitidine and Liposomal Mitoxantrone for Newly Diagnosed AML

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-08-07

  • Heme · AMLRecruitingNot reportedObservationalNCT07670130

    Venetoclax TDM in Newly Diagnosed AML: Exposure-Response and Prognosis

    The First Affiliated Hospital of Soochow University · 1 locations · Updated 2026-08-06

  • Heme · AMLRecruitingNot reportedObservationalNCT06928909

    Leukemia Adapted Protocol

    Baylor College of Medicine · 1 locations · Updated 2026-07-15

  • Heme · AMLRecruitingPhase 1NCT05749276

    Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)

    Nantes University Hospital · 1 locations · Updated 2026-06-25

  • Heme · AMLRecruitingPhase 1NCT06138587

    Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

    Dana-Farber Cancer Institute · 2 locations · Updated 2026-06-17

  • Heme · AMLRecruitingPhase 1NCT05768932

    BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

    SillaJen, Inc. · 17 locations · Updated 2026-06-15

  • Heme · AMLRecruitingPhase 1NCT07617285

    Allogeneic CAR-T(CT0890B) in NKG2DL+ R/R AML

    Peking University People's Hospital · 1 locations · Updated 2026-06-01

  • Heme · AMLRecruitingPhase 1NCT06222580

    SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

    Uma Borate · 4 locations · Updated 2026-05-14

  • Heme · AMLRecruitingPhase 1NCT07374029

    Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

    David Avigan · 1 locations · Updated 2026-05-05

  • Heme · AMLRecruitingPhase 1NCT05101551

    Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy

    Norman J. Lacayo · 9 locations · Updated 2026-04-22

  • Heme · AMLRecruitingPhase 1NCT06146257

    A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes

    GluBio Therapeutics Inc. · 8 locations · Updated 2026-04-13

  • Heme · AMLNot yet recruitingNot applicableNCT07521124

    ABC Maintenance Therapy for AML

    Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · 1 locations · Updated 2026-04-09

  • Heme · AMLRecruitingPhase 1NCT06313437

    Revumenib in Combination With 7+3 + Midostaurin in AML

    Richard Stone, MD · 2 locations · Updated 2026-03-25

  • Heme · AMLRecruitingPhase 4NCT07101588

    Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial

    Chinese PLA General Hospital · 1 locations · Updated 2026-03-20

  • Heme · AMLRecruitingPhase 1NCT05735184

    A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

    Kura Oncology, Inc. · 44 locations · Updated 2026-03-13

  • Heme · AMLRecruitingPhase 1NCT05627232

    Tazemetostat and Palbociclib With CPX-351for R/R AML

    Thomas Jefferson University · 1 locations · Updated 2026-03-12

  • Heme · AMLNot yet recruitingPhase 1NCT07441980

    A Clinical Study to Explore the Safety and Efficacy of CT1390B in Relapsed/ Refractory Acute Myeloid Leukemia

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-03-02

  • Heme · AMLRecruitingPhase 1NCT05558124

    CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML

    H. Lee Moffitt Cancer Center and Research Institute · 1 locations · Updated 2026-02-27

  • Heme · AMLNot yet recruitingNot applicableNCT07386392

    Effect of Hypnosis and Virtual Reality on Anxiety During Treatment for Acute Myeloid Leukemia

    University Hospital, Toulouse · 1 locations · Updated 2026-02-04

  • Heme · AMLRecruitingPhase 1NCT05317403

    Venetoclax to Augment Epigenetic Modification and Chemotherapy

    Medical College of Wisconsin · 1 locations · Updated 2026-01-12

  • Heme · AMLRecruitingPhase 1NCT05597306

    Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia

    Terrence J Bradley, MD · 1 locations · Updated 2026-01-08

  • Heme · AMLRecruitingPhase 1NCT05342584

    Venetoclax Plus Intensive Chemotherapy in AML and Advanced MDS

    Montefiore Medical Center · 1 locations · Updated 2026-01-08

  • Heme · AMLNot yet recruitingNot reportedObservationalNCT07269067

    Automated vs Manual Flow-cytometry Gating for Measurable Residual Disease in Acute Myeloid Leukaemia (DUALFLOW)

    University Hospital, Bordeaux · Locations not reported · Updated 2025-12-08

  • Heme · AMLNot yet recruitingPhase 1NCT07233018

    A Clinical Study to Explore the Safety and Efficacy of CT0991 in Relapsed/ Refractory Acute Myeloid Leukemia

    MEI HENG · 1 locations · Updated 2025-11-18

  • Heme · AMLRecruitingPhase 1NCT06501196

    A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

    BlossomHill Therapeutics · 13 locations · Updated 2025-09-24

  • Heme · AMLRecruitingNot applicableNCT06386302

    Chidamide, Venetoclax, and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2025-08-03

  • Heme · AMLRecruitingPhase 1NCT06880354

    A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

    Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2025-06-03

  • Heme · AMLNot yet recruitingPhase 4NCT06763666

    CLAG+VEN vs CLAG in the Treatment of Relapsed/Refractory AML

    Nanfang Hospital, Southern Medical University · 1 locations · Updated 2025-01-08

  • Heme · AMLNot yet recruitingNot applicableNCT06643195

    Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Re-treatment for Patients With High-Risk Acute Myeloid Leukemia

    Institute of Hematology & Blood Diseases Hospital, China · 4 locations · Updated 2024-12-30

  • Heme · AMLRecruitingNot applicableNCT06643962

    Venetoclax Combined with Intensive Therapy for Acute Myeloid Leukemia Patients with Lower Early Peripheral Blast Clearance Rate After Standard Induction Therapy

    Affiliated Hospital of Nantong University · 1 locations · Updated 2024-11-12

  • Heme · AMLRecruitingNot reportedObservationalNCT05772559

    Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies

    Assistance Publique - Hôpitaux de Paris · 28 locations · Updated 2024-06-26

  • Heme · AMLRecruitingNot reportedObservationalNCT06225128

    Dynamics of Resistance Emergence to Azacitidine-based Therapies in Acute Myeloid Leukemia

    Assistance Publique - Hôpitaux de Paris · 1 locations · Updated 2024-05-29

  • Heme · ALL, AMLRecruitingNot reportedObservationalNCT05326919

    The Patient Cohort of the National Center for Precision Medicine in Leukemia

    Assistance Publique - Hôpitaux de Paris · 3 locations · Updated 2024-05-29

  • Heme · AMLRecruitingNot applicableNCT06329999

    A Prospective, Multicenter, and Exploratory Study of CMGV in the Treatment of Recurrent Adult AML and MDS-EB-2/Elder AML

    Ruijin Hospital · 1 locations · Updated 2024-03-26

  • Heme · AMLRecruitingNot applicableNCT05909293

    Clinical Study Protocol of Maintenance Therapy With Venetoclax in Elderly Patients With AML in First Complete Remission

    The First Affiliated Hospital with Nanjing Medical University · 1 locations · Updated 2023-06-18

Status can change after this sync. The curated list is the other view on this page. Evidence holds the published results.